Single-Use Equipment Proving Useful Managing Biomanufacturing Costs

Single-use technologies improve flexibility and are introducing a new era in operational economy for bioprocessors.

Biopharmaceuticals continue to grow in importance and number as pharmaceu­tical research uncovers new treatment options for new and existing conditions. Growth in emerging economies with im­proved living standards and a rapidly growing middle class is also helping to fuel this transition. 

Although the overall pharmaceuti­cals market is expected to grow at a compounded annual growth rate (CAGR) of 4%-7% to reach $1.3 trillion in 2018 1, significant challenges still exist in the market, including patent cliffs that are already impacting legacy products, mounting and changing regulations, increasingly com­plicated development and manufacturing processes for in-demand drugs (mainly biologics), and instability in the emerging markets.

Due to the unique aseptic requirements for biopharma­ceutical drugs — requirements further compounded by most biologic drugs currently requiring parenteral ad­ministration — the manufacturing process is complex, challenging and inexorably linked to the therapeutic and commercial success of biologic products. For the bio­pharmaceutical industry, both outsourcing partners and technological advancements are proving valuable in over­coming these challenges.

Most notably, single-use systems (SUSs) are offering flexible options for producers looking to drive efficiencies into the biopharmaceutical process. With options for both upstream and downstream processes, the flexible factory concept is becoming the model for cost-effective, asep­tic production, whether companies are pursuing major or emerging markets and improved agility with both small- and large-scale production.

Flexibility from Start to Fill-Finish

In the 2015 Nice Insight Equipment Survey (overall n=560, biotechnology n=208), 91% of respondents claimed to be using bioprocessing equipment. The same survey also in­dicated that quality and performance were by far the most important factors considered when selecting an equip­ment supplier. Though many biopharmaceutical manu­facturers have implemented SUSs at various phases of the production cycle, the decision to transition away from more traditional multi-use/stainless steel systems is significant at every level of implementation.

16Q2_NI_Eq_Report_Sidebar1.jpg

Nice Insight’s 2016 CDMO Outsourcing Survey showed that 50% of those responding outsourced ser­vices for sterile/contained manufacturing and 44% out­sourced for parenteral manufacturing/packaging, both key to bioprocessing. With that, 55% of respondents outsource to CDMOs for mammalian cell line-based development and biomanufacturing.3  As many current SUSs are designed primarily for mammalian cell culti­vation, CDMOs are often some of the earliest adopters of technologies like SUSs. Single-use technology de­velopment continues to improve, and solutions now ex­ist for nearly all upstream and downstream processes at most production volumes. These specific benefits include ease of use, increased capacity and an overall reduction in downtime; however, manufacturers with large production volumes of one specific drug may not experience these benefits.

When in place, SUSs can greatly reduce the need for and frequency of sterilize-in-place (SIP) and clean-in-place (CIP) processes, as well as on-site facilities/equipment associated with these operations, allowing for rapid changeovers of small- and medium-scale pro­duction operations without an increased risk of con­tamination or a large equipment footprint. 5

Without the need for fixed equipment or hard piping, the footprint of SUS-based bioprocessing shrinks, and is made mobile and flexible. Similarly, with consum­able components (tubing, bags, etc.), single pieces of equipment can perform multiple operations. Despite the category’s many advancements over the decades, there are still risks and limitations associated with the implementation and use of single-use technology.5

Quality Materials, Vendors

Vendor reliability and material quality are critical to the successful implementation and maintenance of an SUS. Though many upstream processes are lower risk in general, due to most liquids being recoverable media or buffer solutions, quality concerns magnify with downstream processes, such as protein purifica­tion, one of the final steps in biomanufacturing. SUS equipment failure at these stages presents a greater risk.4 Components are often delivered sterile/ready-to-use and the integrity of items such as bags may be verified at delivery, but the fragility of plastic items greatly increases the risk of damage between delivery and use. Point-of-use testing — via helium integrity or pressure decay — can often help minimize these risks/failures, but vendor selection and material quality are also critical.4

Lower Risk for Global Operations

Emerging markets (Brazil, Russia, India, China, Mexico and Turkey) are growing more rapidly than developed markets and will account for nearly 50% of absolute growth by 2018,but the risks involved with penetrating this space are great. These markets often favor local investment over imports, meaning partnership with a local CDMO may be a more reli­able option, but SUSs also make the flexible factory, or single-use facility, concept 5 a possibility for com­panies looking to pursue emerging markets and an­swer demand for generic versions of biopharmaceu­ticals. Rapid entry and low financial risk are key to providing competitively priced options. Single-use operations provide the flexibility and mobility re­quired to meet these demands.

As single-use technology continues to improve, of­fering greater capacity, more durable materials and even greater flexibility, their appeal will only grow for biopharmaceutical processors. To speed entry into new markets, manage supply chain risk and take ad­vantage of advanced processes, CDMOs will remain a viable option to access the advantages of single-use technology production.

References

  1. Global Outlook for Medicines Through 2018, IMS Institute for Healthcare Informatics, 2014.http://www.imshealth.com/en/thought-leadership/ims-institute/reports/global-outlook-for-medicines-through-2018.
  2. The 2015 Nice Insight Equipment Survey. Jan 2015. http://www.niceinsight.com.
  3. The 2016 Nice Insight Contract Development & Manufacturing Survey. Jan 2016.http://www.niceinsight.com.
  4. Sherrick, A., “Single-Use Integrity Testing Goes Mobile: Manufacturers adopting point-of-use testing with flexibility and mobility.” Pharmaceuti­cal Manufacturing, Nov 2015.http://www.pharmamanufacturing.com/ar­ticles/2015/single-use-integrity-testing-goes-mobile/.
  5. Cattaruzza, C. and Ribault, S., “Process and Facility Design for a Mono­clonal Antibody Facility: Single Use Technology delivers strategic flexibility to EMD Millipore,” Pharmaceutical Manufacturing, Oct 2015. http://www.pharmamanufacturing.com/articles/2015/process-facility-design-monoclonal-antibody-facility/?show=all.

Nice Insight

Nice Insight, established in 2010, is the research division of That’s Nice, A Science Agency, providing data and analysis from proprietary annual surveys, custom primary qualitative and quantitative research as well as extensive secondary research. Current annual surveys include The Nice Insight Contract Development & Manufacturing (CDMO/CMO), Survey The Nice Insight Contract Research - Preclinical and Clinical (CRO) Survey, The Nice Insight Pharmaceutical Equipment Survey, and The Nice Insight Pharmaceutical Excipients Survey.